UniProt Q86SG6 · PDB · AlphaFold · Substrate: MBP · Clone: aa 1-322
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Lorlatinib | 81.2% | 18.8% | 97.24 | 0.694 |
| 2 | Midostaurin | 74.3% | 25.7% | 78.64 | 0.500 |
| 3 | Axitinib | 39.9% | 60.1% | 93.23 | 0.688 |
| 4 | Ruxolitinib | 30.1% | 69.9% | 98.25 | 0.592 |
| 5 | Vemurafenib | 28.1% | 71.9% | 96.49 | 0.598 |
| 6 | Baricitinib | 20.0% | 80.0% | 97.99 | 0.616 |
| 7 | Lapatinib | 20.0% | 80.0% | 99.25 | 0.616 |
| 8 | Bosutinib | 19.8% | 80.2% | 87.22 | 0.555 |
| 9 | Dasatinib | 18.9% | 81.1% | 87.97 | 0.699 |
| 10 | Fostamatinib | 18.3% | 81.7% | 96.74 | 0.613 |
| 11 | Lenvatinib | 17.7% | 82.3% | 97.74 | 0.726 |
| 12 | Nilotinib | 17.2% | 82.8% | 96.49 | 0.765 |
| 13 | Nintedanib | 16.5% | 83.5% | 90.23 | 0.608 |
| 14 | Everolimus | 16.4% | 83.6% | 100.00 | 0.706 |
| 15 | Palbociclib | 14.4% | 85.6% | 98.75 | 0.673 |
| 16 | Regorafenib | 13.3% | 86.7% | 95.99 | 0.719 |
| 17 | Gefitinib | 13.2% | 86.8% | 99.25 | 0.650 |
| 18 | Sirolimus | 12.4% | 87.6% | 100.00 | 0.708 |
| 19 | Alectinib | 11.8% | 88.2% | 95.49 | 0.651 |
| 20 | Temsirolimus | 11.7% | 88.3% | 100.00 | 0.740 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 1.70
- Epithelial log2(TPM+1): 2.29
- Fold change: -0.59
- Status: No significant change
Selectivity landscape vs inhibition on NEK8
Each point is one of the 92 approved drugs; color = inhibition % on NEK8.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…